Evaluating nivolumab with isolated limb perfusion for melanoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and effectiveness of combining nivolumab, an immunotherapy drug, with isolated limb perfusion (ILP) in patients with in-transit metastases of melanoma. The study will begin with a Phase Ib component involving 20 patients, who will be monitored for at least three months to evaluate safety and efficacy. An independent data safety monitoring board will oversee the trial, ensuring participant safety and making recommendations regarding the continuation of the study into Phase II based on safety findings.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Male or female aged above 18 years.
2. Signed and dated written informed consent before the start of specific protocol procedures.
3. Histologically or cytologically proven in-transit metastases of malignant melanoma with or without regional lymph node metastases (AJCC v8 stage N1c, N2c and N3c).
4. Measurable disease with at least 1 metastasis measuring at least 5mm
5. ECOG performance status of 0-2

Exclusion Criteria

1. 1\. Life expectancy of less than 6 months
2. Inability to understand given information or undergo study procedures according to protocol.
3. Pregnant or breast-feeding. Women of childbearing potential must have a negative pregnancy test performed within 24 hours before the administration of study drug.
4. Patients must agree to follow instructions for method of contraception for 5 months (women) and 7 months (males) after treatment.
5. Active cardiac conditions, including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), significant arrhythmias and severe valvular disease that precludes general anaesthesia.
6. History or evidence of clinically significant pulmonary disease e.g., severe COPD that precludes general anesthesia.
7. Reduced renal function defined as S-Creatinine \>=1.5xULN
8. Reduced hepatic function (defined as ASAT, ALAT, bilirubin \>1.5 ULN and PK-INR \>1.5) or a medical history of liver cirrhosis or portal hypertension.
9. Reduced blood leukocytes or platelets defined as a leucocyte count \< 2.0x109/L and thrombocyte count \<100x109/L.
10. Active, autoimmune disease. Subjects are permitted to enrolment if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger.
11. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
12. A condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 30 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \>10 mg daily prednisone equivalents are permitted.
13. Has an active infection requiring systemic therapy.
14. Has received a live vaccine within 30 days prior to the first dose of trial treatment and 3 months after treatment.
15. Concomitant therapy with any of the following: IL 2 or other non-study immunotherapy regimens; cytotoxic chemotherapy except melphalan (ILP); other investigational therapies within 30 days before trial treatment and 3 months after trial treatment.

Where it's running

• Netherlands Cancer Institute
  Amsterdam, Netherlands Recruiting
• Sahlgrenska University Hospital
  Gothenburg, Sweden Recruiting
• Erasmus MC Cancer Institute
  Groningen, Netherlands Not yet recruiting
• Erasmus MC Cancer Institute
  Rotterdam, Netherlands Not yet recruiting

Study contacts

• Study coordinator: Roger Olofsson Bagge, MD, PhD
• Email: roger.olofsson.bagge@gu.se
• Phone: +46 31 3428207

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Relatlimab, nivolumab, and ipilimumab for melanoma that has spread to the brain

  This trial will test whether the combination of relatlimab, nivolumab, and ipilimumab can help adults with melanoma brain metastases, including those with and without symptoms.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT06712927

• Triplet combination of Relatlimab, Nivolumab, and Ipilimumab in first-line metastatic melanoma

  A first-line trial tests whether a three-drug combo can help people with metastatic melanoma, starting at a recommended dose.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06683755

• Oral Alintegimod with Ipilimumab followed by Nivolumab for advanced cancer

  This study is testing if a new oral medication called Alintegimod, combined with two other cancer treatments, can help people with advanced solid tumors feel better and live longer.

  Recruiting at 4 sites Phase 1/2 7 Hills Pharma, LLC · Aurora, Colorado and 4 other locations · NCT06362369

• Combining two experimental drugs for advanced melanoma treatment

  This study is testing if a new combination of two experimental drugs can help people with advanced melanoma more than the current approved treatments.

  Recruiting at 92 sites Phase 3 Regeneron Pharmaceuticals · Chandler, Arizona and 112 other locations · NCT06246916

• Local injection of ipilimumab and nivolumab for high-risk stage II melanoma

  This study is testing if injecting a combination of two immune-boosting drugs directly into the skin can help people with high-risk stage II melanoma by reducing the chance of cancer spreading.

  Recruiting at 2 sites Phase 1/2 The Netherlands Cancer Institute · Amsterdam and 5 other locations · NCT06240143

• Combining Sarilumab with Other Treatments for Advanced Melanoma

  This study is testing a new combination of treatments for people with advanced melanoma to see if it helps them feel better and live longer.

  Recruiting at 4 sites Phase 2 NYU Langone Health · Los Angeles, California and 3 other locations · NCT05428007

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.